Efficacy of Leuprorelin Acetate Depot in the Treatment of Prostatic Cancer: Results of a Long-Term Follow-Up Study

  • M. Wiesel
  • E. Kienle
  • G. Lübben
  • The German Leuprorelin Study Group
Conference paper

Abstract

The hormone dependency of prostatic cancer and its clinical responsiveness to androgen deprivation were described over 50 years ago by Huggins and Hodges (1941). About 80% of prostatic tumors show a primary response to androgen-ablative procedures. Until recently, orchiectomy and estrogen therapy were regarded as the state of the art, although psychological problems associated with orchiectomy and the risk of serious cardiovascular side effects from estrogen therapy were known and had been described at length in the literature (Bailar and Byar 1970; The Leuprorelin Study Group 1984).

Keywords

Placebo Estrogen Adenocarcinoma Testosterone Androgen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bailar JC III, Byar DP (1970) Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 26: 257PubMedCrossRefGoogle Scholar
  2. Cirkel U et al (1992) Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study. Int J Drug Ther 14 [Supp. A]Google Scholar
  3. Dowsett M et al (1992) Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Int J Drug Ther 14 [Supp. A]Google Scholar
  4. Fornara P (1992) Multicenter-Studie mit Enantone Monats-Depot — Langzeitsverlaufskontrolle. In: Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. Springer Berlin Heidelberg New York TokyoGoogle Scholar
  5. Gerhard I et al (1992) Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Int J Drug Ther 14 [Supp. A]Google Scholar
  6. Huggins C, Hodges CV (1941) Studies on Prostatic Cancer I. The effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostata. Res 1: 292Google Scholar
  7. International Union Against Cancer (1987) TNM classification of malignant tumours. 4th a fully revised edn. Springer Berlin Heidelberg New York TokyoGoogle Scholar
  8. Johnson E, Seely J, White W, de Sombre E (1976) Endocrine-dependent rat mammary tumor regression: use of gonadotropin releasing hormone analog. Science 194: 329–30PubMedCrossRefGoogle Scholar
  9. O’Brien A, Grainger R, Butler MR (1992) Experience with leuprorelin acetate as a depot formulation for prostate cancer in a long-term follow-up study. In: Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. Springer Berlin Heidelberg New York TokyoGoogle Scholar
  10. Ogawa Y (1992) Monthly microcapsule-depot form of LHRH agonist, leuprorelin acetate (Enantone Depot): Formulation and pharmacokinetics in animals. Eur J Hosp Pharm Vol 2, No. 4Google Scholar
  11. Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, Guinan P (1985) Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Urology 26: 117PubMedCrossRefGoogle Scholar
  12. Smith JA Jr (1984) Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J Urol 131: 1110PubMedGoogle Scholar
  13. Soloway MS (1984) Newer methods of hormonal therapy for prostate cancer. Urology 24 [Suppl 5] 30PubMedGoogle Scholar
  14. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 1281CrossRefGoogle Scholar
  15. Toguchi H (1992) Formulation study of leuprorelin acetate to improve clinical performance. Int J Drug Ther 14 [Supp. A]Google Scholar
  16. Turkes AO, Peeling WB, Griffiths K (1987) Management of patients with advanced carcinoma of the prostate: a randomized phase III trial of zoladex against castration by the British Prostate Group. In: (eds) Hormonal therapy of prostatic diseases. Motta M, Serio M, MedicomGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. Wiesel
  • E. Kienle
  • G. Lübben
  • The German Leuprorelin Study Group

There are no affiliations available

Personalised recommendations